uniQure (NASDAQ:QURE) Was Coveraged By B. Riley FBR with $50 Target.

June 29, 2018 - By Noel Courtney

uniQure N.V. (NASDAQ:QURE) Corporate Logo

What Price Target Has B. Riley FBR Given uniQure (NASDAQ:QURE)

B. Riley FBR revealed on Thursday morning a recent note that it started coverage on uniQure (NASDAQ:QURE) that has $50 target on QURE and “Buy” rating.

uniQure N.V. (NASDAQ:QURE) Ratings Coverage

In total 7 analysts cover uniQure NV (NASDAQ:QURE). “Buy” rating has 7, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 8 are the (NASDAQ:QURE)’s analyst reports since January 3, 2018 according to StockzIntelligence Inc. On Wednesday, May 16 the rating was initiated by Wells Fargo with “Buy”. On Wednesday, May 23 the rating was maintained by Chardan Capital Markets with “Buy”. The company rating was maintained by H.C. Wainwright on Thursday, March 15. On Tuesday, March 20 the stock of uniQure N.V. (NASDAQ:QURE) has “Buy” rating given by Janney Capital. On Wednesday, January 3 the rating was initiated by Janney Capital with “Buy”. On Monday, May 7 Leerink Swann maintained the shares of QURE in report with “Buy” rating.

QURE is reaching $37.69 during the last trading session, after decreased 2.24%.uniQure N.V. has volume of 98,076 shares. Since June 29, 2017 QURE has risen 534.87% and is uptrending. QURE outperformed the S&P500 by 522.30%.

On August, 14 is expected uniQure N.V. (NASDAQ:QURE)’s earnings report, Faxor reports. earnings per share of $-0.64 is 22.89 % up from 2017’s $-0.83 EPS. After $-0.59 earnings per share was published last quarter, analysts now see negative EPS growth of 8.47 % for uniQure N.V..

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.The firm is worth $1.40 billion. The firm develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.Currently it has negative earnings.

For more uniQure N.V. (NASDAQ:QURE) news posted recently go to: Benzinga.com, Nasdaq.com, Fool.com, Benzinga.com or Benzinga.com. The titles are as follows: “3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy” posted on June 28, 2018, “uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B” on June 28, 2018, “Are These 3 Red-Hot Gene Therapy Stocks Still Buys?” with a publish date: June 25, 2018, “AMT 061” and the last “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” with publication date: June 21, 2018.

uniQure N.V. (NASDAQ:QURE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.